Short term treatment with lithium carbonate as adjunct to radioiodine treatment for long-lasting Graves' hyperthyroidism
Lithium carbonate is primarily used for the treatment of patients with bipolar affective disorders. Initial treatment of Graves' hyperthyroidism (GHT) with antithyroid drugs (ATD) has limitations at over 50% of treated patients because of significant side effects and relatively high relapses of...
Gespeichert in:
| Veröffentlicht in: | Hellenic journal of nuclear medicine 2015-09, Vol.18 (3), p.186 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 186 |
| container_title | Hellenic journal of nuclear medicine |
| container_volume | 18 |
| creator | Sekulić, Vladan Rajić, Milena P Vlajković, Marina Ž Ilić, Slobodan S Stević, Miloš Lj Kojić, Marko M |
| description | Lithium carbonate is primarily used for the treatment of patients with bipolar affective disorders. Initial treatment of Graves' hyperthyroidism (GHT) with antithyroid drugs (ATD) has limitations at over 50% of treated patients because of significant side effects and relatively high relapses of the disease after drugs withdrawal. Till now, the influence of LiCO₃on RIT outcome was mainly studied in patients with recent onset of GHT, and results were contradicted. Meta-analysis of case-control studies showed higher rated hypothyroidism in patients with mood disorders treated with LiCO₃(121/869) than in controls (10/578). Although in a small number of patients (n=28) with long-lasting GHT, preliminary results of ours showed that ¹³¹I treatment with LiCO₃for 7 days significantly improved the efficacy of RIT versus the non-LiCO₃treated patients (P |
| doi_str_mv | 10.1967/s002449910300 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_26574688</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>26574688</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-6b00616cfda9ef4dc5517346d67dd330cc5f8917eb4bffef37070be0ace930bf3</originalsourceid><addsrcrecordid>eNpNkDtPwzAYRT2AaCmMrMgbU-Bz7NjxiCooSJUYgLnys3GVxJHtAv33VAIklnOnc4eD0BWBWyK5uMsANWNSEqAAJ2hOhISqYbWYofOcdwANF7w9Q7OaN4Lxtp2jr9cupoKLSwMuyakyuLHgz1A63B8R9gM2Kuk4quKwyljZ3X40RyHipGyIIdowun-qjwn3cdxWvcoljFu8SurD5RvcHSaXSndIMdiQhwt06lWf3eXvLtD748Pb8qlav6yel_fraqoJKRXXAJxw462SzjNrmoYIyrjlwlpKwZjGt5IIp5n23nkqQIB2oIyTFLSnC3T98zvt9eDsZkphUOmw-UtAvwEqOF_F</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Short term treatment with lithium carbonate as adjunct to radioiodine treatment for long-lasting Graves' hyperthyroidism</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Sekulić, Vladan ; Rajić, Milena P ; Vlajković, Marina Ž ; Ilić, Slobodan S ; Stević, Miloš Lj ; Kojić, Marko M</creator><creatorcontrib>Sekulić, Vladan ; Rajić, Milena P ; Vlajković, Marina Ž ; Ilić, Slobodan S ; Stević, Miloš Lj ; Kojić, Marko M</creatorcontrib><description>Lithium carbonate is primarily used for the treatment of patients with bipolar affective disorders. Initial treatment of Graves' hyperthyroidism (GHT) with antithyroid drugs (ATD) has limitations at over 50% of treated patients because of significant side effects and relatively high relapses of the disease after drugs withdrawal. Till now, the influence of LiCO₃on RIT outcome was mainly studied in patients with recent onset of GHT, and results were contradicted. Meta-analysis of case-control studies showed higher rated hypothyroidism in patients with mood disorders treated with LiCO₃(121/869) than in controls (10/578). Although in a small number of patients (n=28) with long-lasting GHT, preliminary results of ours showed that ¹³¹I treatment with LiCO₃for 7 days significantly improved the efficacy of RIT versus the non-LiCO₃treated patients (P<0.001). Lithium treated patients were cured faster (12 of 13 patients were cured after one month) than those treated only with ¹³¹I (8 patients were cured after one and 11/15 patients after 12 months). Fewer patients treated with ¹³¹I and LiCO₃had persistent hyperthyroidism than those treated with ¹³¹I alone. There were no toxic effects of LiCO₃during 7 days treatment.
These observations indicate of that short-term treatment with LiCO₃in GHT patients as adjunct to ¹³¹I-NaI improves the efficacy of RIT, prevents transient exacerbation of hyperthyroidism, early induction of hypothyroidism and does not worsen ophthalmopathy.</description><identifier>ISSN: 1790-5427</identifier><identifier>DOI: 10.1967/s002449910300</identifier><identifier>PMID: 26574688</identifier><language>eng</language><publisher>Greece</publisher><subject>Antithyroid Agents - administration & dosage ; Chemoradiotherapy - methods ; Chemotherapy, Adjuvant - methods ; Chronic Disease ; Drug Administration Schedule ; Graves Disease - diagnosis ; Graves Disease - therapy ; Humans ; Iodine Radioisotopes - administration & dosage ; Lithium Carbonate - administration & dosage ; Longitudinal Studies ; Radiopharmaceuticals - administration & dosage ; Treatment Outcome</subject><ispartof>Hellenic journal of nuclear medicine, 2015-09, Vol.18 (3), p.186</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26574688$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sekulić, Vladan</creatorcontrib><creatorcontrib>Rajić, Milena P</creatorcontrib><creatorcontrib>Vlajković, Marina Ž</creatorcontrib><creatorcontrib>Ilić, Slobodan S</creatorcontrib><creatorcontrib>Stević, Miloš Lj</creatorcontrib><creatorcontrib>Kojić, Marko M</creatorcontrib><title>Short term treatment with lithium carbonate as adjunct to radioiodine treatment for long-lasting Graves' hyperthyroidism</title><title>Hellenic journal of nuclear medicine</title><addtitle>Hell J Nucl Med</addtitle><description>Lithium carbonate is primarily used for the treatment of patients with bipolar affective disorders. Initial treatment of Graves' hyperthyroidism (GHT) with antithyroid drugs (ATD) has limitations at over 50% of treated patients because of significant side effects and relatively high relapses of the disease after drugs withdrawal. Till now, the influence of LiCO₃on RIT outcome was mainly studied in patients with recent onset of GHT, and results were contradicted. Meta-analysis of case-control studies showed higher rated hypothyroidism in patients with mood disorders treated with LiCO₃(121/869) than in controls (10/578). Although in a small number of patients (n=28) with long-lasting GHT, preliminary results of ours showed that ¹³¹I treatment with LiCO₃for 7 days significantly improved the efficacy of RIT versus the non-LiCO₃treated patients (P<0.001). Lithium treated patients were cured faster (12 of 13 patients were cured after one month) than those treated only with ¹³¹I (8 patients were cured after one and 11/15 patients after 12 months). Fewer patients treated with ¹³¹I and LiCO₃had persistent hyperthyroidism than those treated with ¹³¹I alone. There were no toxic effects of LiCO₃during 7 days treatment.
These observations indicate of that short-term treatment with LiCO₃in GHT patients as adjunct to ¹³¹I-NaI improves the efficacy of RIT, prevents transient exacerbation of hyperthyroidism, early induction of hypothyroidism and does not worsen ophthalmopathy.</description><subject>Antithyroid Agents - administration & dosage</subject><subject>Chemoradiotherapy - methods</subject><subject>Chemotherapy, Adjuvant - methods</subject><subject>Chronic Disease</subject><subject>Drug Administration Schedule</subject><subject>Graves Disease - diagnosis</subject><subject>Graves Disease - therapy</subject><subject>Humans</subject><subject>Iodine Radioisotopes - administration & dosage</subject><subject>Lithium Carbonate - administration & dosage</subject><subject>Longitudinal Studies</subject><subject>Radiopharmaceuticals - administration & dosage</subject><subject>Treatment Outcome</subject><issn>1790-5427</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkDtPwzAYRT2AaCmMrMgbU-Bz7NjxiCooSJUYgLnys3GVxJHtAv33VAIklnOnc4eD0BWBWyK5uMsANWNSEqAAJ2hOhISqYbWYofOcdwANF7w9Q7OaN4Lxtp2jr9cupoKLSwMuyakyuLHgz1A63B8R9gM2Kuk4quKwyljZ3X40RyHipGyIIdowun-qjwn3cdxWvcoljFu8SurD5RvcHSaXSndIMdiQhwt06lWf3eXvLtD748Pb8qlav6yel_fraqoJKRXXAJxw462SzjNrmoYIyrjlwlpKwZjGt5IIp5n23nkqQIB2oIyTFLSnC3T98zvt9eDsZkphUOmw-UtAvwEqOF_F</recordid><startdate>201509</startdate><enddate>201509</enddate><creator>Sekulić, Vladan</creator><creator>Rajić, Milena P</creator><creator>Vlajković, Marina Ž</creator><creator>Ilić, Slobodan S</creator><creator>Stević, Miloš Lj</creator><creator>Kojić, Marko M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>201509</creationdate><title>Short term treatment with lithium carbonate as adjunct to radioiodine treatment for long-lasting Graves' hyperthyroidism</title><author>Sekulić, Vladan ; Rajić, Milena P ; Vlajković, Marina Ž ; Ilić, Slobodan S ; Stević, Miloš Lj ; Kojić, Marko M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-6b00616cfda9ef4dc5517346d67dd330cc5f8917eb4bffef37070be0ace930bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antithyroid Agents - administration & dosage</topic><topic>Chemoradiotherapy - methods</topic><topic>Chemotherapy, Adjuvant - methods</topic><topic>Chronic Disease</topic><topic>Drug Administration Schedule</topic><topic>Graves Disease - diagnosis</topic><topic>Graves Disease - therapy</topic><topic>Humans</topic><topic>Iodine Radioisotopes - administration & dosage</topic><topic>Lithium Carbonate - administration & dosage</topic><topic>Longitudinal Studies</topic><topic>Radiopharmaceuticals - administration & dosage</topic><topic>Treatment Outcome</topic><toplevel>online_resources</toplevel><creatorcontrib>Sekulić, Vladan</creatorcontrib><creatorcontrib>Rajić, Milena P</creatorcontrib><creatorcontrib>Vlajković, Marina Ž</creatorcontrib><creatorcontrib>Ilić, Slobodan S</creatorcontrib><creatorcontrib>Stević, Miloš Lj</creatorcontrib><creatorcontrib>Kojić, Marko M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Hellenic journal of nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sekulić, Vladan</au><au>Rajić, Milena P</au><au>Vlajković, Marina Ž</au><au>Ilić, Slobodan S</au><au>Stević, Miloš Lj</au><au>Kojić, Marko M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Short term treatment with lithium carbonate as adjunct to radioiodine treatment for long-lasting Graves' hyperthyroidism</atitle><jtitle>Hellenic journal of nuclear medicine</jtitle><addtitle>Hell J Nucl Med</addtitle><date>2015-09</date><risdate>2015</risdate><volume>18</volume><issue>3</issue><spage>186</spage><pages>186-</pages><issn>1790-5427</issn><abstract>Lithium carbonate is primarily used for the treatment of patients with bipolar affective disorders. Initial treatment of Graves' hyperthyroidism (GHT) with antithyroid drugs (ATD) has limitations at over 50% of treated patients because of significant side effects and relatively high relapses of the disease after drugs withdrawal. Till now, the influence of LiCO₃on RIT outcome was mainly studied in patients with recent onset of GHT, and results were contradicted. Meta-analysis of case-control studies showed higher rated hypothyroidism in patients with mood disorders treated with LiCO₃(121/869) than in controls (10/578). Although in a small number of patients (n=28) with long-lasting GHT, preliminary results of ours showed that ¹³¹I treatment with LiCO₃for 7 days significantly improved the efficacy of RIT versus the non-LiCO₃treated patients (P<0.001). Lithium treated patients were cured faster (12 of 13 patients were cured after one month) than those treated only with ¹³¹I (8 patients were cured after one and 11/15 patients after 12 months). Fewer patients treated with ¹³¹I and LiCO₃had persistent hyperthyroidism than those treated with ¹³¹I alone. There were no toxic effects of LiCO₃during 7 days treatment.
These observations indicate of that short-term treatment with LiCO₃in GHT patients as adjunct to ¹³¹I-NaI improves the efficacy of RIT, prevents transient exacerbation of hyperthyroidism, early induction of hypothyroidism and does not worsen ophthalmopathy.</abstract><cop>Greece</cop><pmid>26574688</pmid><doi>10.1967/s002449910300</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1790-5427 |
| ispartof | Hellenic journal of nuclear medicine, 2015-09, Vol.18 (3), p.186 |
| issn | 1790-5427 |
| language | eng |
| recordid | cdi_pubmed_primary_26574688 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Antithyroid Agents - administration & dosage Chemoradiotherapy - methods Chemotherapy, Adjuvant - methods Chronic Disease Drug Administration Schedule Graves Disease - diagnosis Graves Disease - therapy Humans Iodine Radioisotopes - administration & dosage Lithium Carbonate - administration & dosage Longitudinal Studies Radiopharmaceuticals - administration & dosage Treatment Outcome |
| title | Short term treatment with lithium carbonate as adjunct to radioiodine treatment for long-lasting Graves' hyperthyroidism |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T16%3A55%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Short%20term%20treatment%20with%20lithium%20carbonate%20as%20adjunct%20to%20radioiodine%20treatment%20for%20long-lasting%20Graves'%20hyperthyroidism&rft.jtitle=Hellenic%20journal%20of%20nuclear%20medicine&rft.au=Sekuli%C4%87,%20Vladan&rft.date=2015-09&rft.volume=18&rft.issue=3&rft.spage=186&rft.pages=186-&rft.issn=1790-5427&rft_id=info:doi/10.1967/s002449910300&rft_dat=%3Cpubmed%3E26574688%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/26574688&rfr_iscdi=true |